2024 Clinical Neuromuscular Pathology Reading List

Reading List

Please click below to access the 2024 Clinical Neuromuscular Pathology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Recognize clinicopathological features of immune peripheral nerve disorders, their mechanisms, and therapy
• Distinguish pathologic features of infectious neuropathies and granulomatous myopathies
• Describe histopathological features in acquired muscle disorders (antisynthetase syndrome, IBM, and SLONM) and their management
• Discuss the pathology of hereditary myopathies

Core Competencies

• Medical Knowledge
• Patient Care
• Practice-Based Learning and Improvement

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within 24 hours of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 15 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry and Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved this activity as part of a comprehensive self-assessment (SA) CME activity, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of continuing certification.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2024 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

Mazen Mohammad Dimachkie, MD, Chair, University of Kansas Medical Center
Disclosures: Received compensation for services as a consultant to Abcuro, Amazentis/Vandria, ArgenX, Astellas, Catalyst, Cello, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, EcoR1, EMD Serono/Merck, Janssen, Kezar, MDA, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, TACT, Abata/Third Rock, and UCB Biopharma; receive compensation for serving on LABCORP/COVANCE as DMC member; received research grant support from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma/RaPharma, Viromed/Healixmith & TMA; receive royalties from UPTODATE.

Michelle Lynn Mauermann, MD, Vice Chair, Mayo Clinic – Rochester
Disclosures: Received research support from Alnylam and IONIS pharmaceuticals for clinical trials; received Oxford publishing royalties for Autonomic Disorders book

Rocio Carolina Garcia Santibanez, MD, Emory Brain Health Center
Disclosures: Nothing to disclose.

Ahmed Mohamed Attia El-Dokla, MD, NY Neuromuscular Healthcare, PC
Disclosures: Nothing to disclose.

Shalini Mahajan, MD, Cedars-Sinai Medical Center
Disclosures: Received research grant from Dysimmune Diseases Foundation.

Raghav Govindarajan, MD, St. Elizabeth Medical Group, Illinois
Disclosures: Received personal compensation for serving as a consultant for Janssen, UCB, Argenx, Amylyx; received personal compensation for serving on a scientific advisory or data safety monitoring board for DSMB, chair for Apellis; received personal compensation for serving on a speakers’ bureau for Argenx, Alexion, Abbvie, and Biohaven; received royalties from Taylor and Francis

Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Received personal compensation for serving as a consultant for Argenx: one time board meeting participation for treatment of myasthenia gravis; consulting service for treatment of DOK-7 congenital myasthenic syndrome; received personal compensation for serving as Associate editor of Neurology Genetics; received research support from MDA, Minnesota Regenerative Medicine, and Mayo Clinic.

Aziz Shaibani, MD, Nerve and Muscle Center of Texas
Disclosures: Nothing to disclose.

Anthony A. Amato, MD, Brigham and Women's Hospital
Disclosures: Received personal compensation for serving as a consultant on medical advisory boards for Johnson & Johnson, Abcuro; received compensation for serving on a scientific advisory or data safety monitoring board for FDA; received personal compensation for serving as Associate Editor for Neurology; received research support as site PI on several research trials: Abcuro, Pharnext.

Mohamed Kazamel, MD, University of Alabama at Birmingham
Disclosures: Receives compensation for being a consultant for Alnylam Pharmaceuticals, including expertise on acute hepatic porphyria.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326